Rocket Pharmaceuticals Cuts 30% of Staff, Refocuses on Heart Gene Therapies
Rocket Pharmaceuticals announced on July 24, 2025, that it will reduce its workforce by approximately 30% as part of a major strategic reorganization aimed at narrowing its focus on cardiovascular gene therapy programs24.
The company will prioritize its adeno-associated virus (AAV) cardiovascular platform, including ongoing clinical programs for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy, and BAG3-associated dilated cardiomyopathy2.
Rocket will continue advancing regulatory activities for KRESLADI, a treatment for severe leukocyte adhesion deficiency-I2.
The restructuring, including layoffs and other cost-saving actions, is expected to lower operating expenses by almost 25% over the next 12 months2.
Rocket projects that with these changes, its current cash reserves will be sufficient to fund operations into the second quarter of 20272.
Some clinical programs previously in focus, such as those for Fanconi Anemia and Pyruvate Kinase Deficiency, will be delayed as a result of the new strategy. FDA approval for Fanconi Anemia therapy is now delayed beyond previous 2026 expectations2.
CEO Gaurav Shah stated the prioritization aims to focus on programs with the highest near-term patient impact and long-term potential for Rocket2.
Sources:
2. https://ca.investing.com/news/company-news/rocket-pharmaceuticals-cuts-workforce-by-30-to-focus-on-heart-therapies-93CH-4116506